Corium International, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Corium International, Inc. - overview
Established
1999
Location
Grand Rapids, MI, US
Primary Industry
Biotechnology
About
Corium International, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative transdermal and topical drug delivery systems. Founded in 1999 and headquartered in Grand Rapids, US, Corium International, Inc. develops advanced transdermal delivery systems.
The company underwent a significant transition when it was acquired by Gurnet Point Capital in 2018, marking a shift from public to private ownership. Gary Cleary is noted as the founder, while Perry Sternberg serves as the current CEO. The company has engaged in a total of 5 funding rounds, with its most recent investment being a GROWTH round in April 2014, which raised USD 100. 00 mn from Webster Equity Partners, matching the total amount raised since inception.
Corium International focuses on developing advanced transdermal and topical drug delivery systems aimed at improving patient adherence and therapeutic outcomes. Their product lineup includes a range of innovative formulations that target various health conditions, leveraging proprietary technology to facilitate effective drug delivery. The company primarily serves the North American and global markets, positioning its offerings to meet a diverse array of healthcare needs. In the fiscal year 2017, Corium International reported a revenue of USD 31.
86 mn. The company's financial performance also indicated an EBITDA loss of USD 37. 97 mn for the same year, reflecting the investment in research and development activities in the biopharmaceutical sector. Corium International plans to utilize its recent funding to enhance its product development pipeline and explore new therapeutic areas.
Future initiatives include launching new transdermal products aimed at unmet medical needs, with potential entry into new markets in Europe and Asia by the end of 2025. The funding received in April 2014 will support these strategic initiatives, focusing on expanding the company's footprint and developing innovative solutions for patients. The firm aims to strengthen its market position following its transition to private ownership, leveraging the financial backing from Gurnet Point Capital.
Current Investors
Webster Equity Partners, Gurnet Point Capital, Essex Woodlands
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.coriumgroup.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Corium International, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Corium International, Inc. | - | ||||||||
| Public to Private, Secondary Buyout | Completed | Corium International, Inc. | - |
Displaying 1 - 2 of 2
Corium International, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.